Market Overview:
The global Bartter Syndrome drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of Bartter Syndrome, rising awareness about the condition, and technological advancements in the field of drug development. Based on type, NSAIDs (nonsteroidal anti-inflammatory drugs) are expected to dominate the global Bartter Syndrome drugs market during the forecast period. This is due to their high efficacy and safety profile compared with other types of drugs used for treating Bartter Syndrome. RAAS inhibitors are also expected to witness significant growth during the forecast period owing to their ability to improve renal function in patients with Bartter Syndrome.
Product Definition:
Bartter Syndrome Drugs are a type of medication used to treat Bartter Syndrome, a rare genetic disorder that affects the kidneys. These drugs help to regulate the levels of salts and minerals in the body, which can become imbalanced in people with Bartter Syndrome.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs):
NSAIDs are a class of drug that inhibits the body's cyclooxygenase enzyme. This enzyme is responsible for producing prostaglandins, which cause pain and inflammation. NSAIDs competitively inhibit this reaction and produce analgesic (pain reducing) effects by decreasing the production of prostaglandins in patients with inflammatory conditions including articular cartilage damage from osteoarthritis or rheumatoid arthritis.
RAAS Inhibitors:
RAAS inhibitors are used to treat symptoms of hyper and hypoglycemia. They work by improving the ability of the body to maintain blood glucose levels. The drugs in this category include names such as Exenatide, Nesina, Sogroya, and Adcetris. These drugs have been approved for use in patients with severe cases of hyperglycemic conditions associated with Bartter syndrome (BS).
Application Insights:
Hospital pharmacies held the largest share of over 70.0% in 2017 owing to the high usage of aspirin and other NSAIDs for pain management, fever reduction, and treatment of sports injuries among others in hospital settings. The growing prevalence of chronic diseases such as heart conditions, hypertension, diabetes mellitus type 2 is also expected to contribute towards segment growth during the forecast period.
The retail pharmacies segment is anticipated to witness significant growth over the forecast period due to rising awareness about health issues among consumers especially in developing countries like China and India where online healthcare shopping has become a trend recently. Rising preference for purchasing medicines from local stores due to convenience along with availability of generic drugs at affordable prices are likely to fuel industry expansion during this period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of key players, favorable reimbursement policies, and increasing healthcare expenditure are some factors driving the growth. In addition, growing awareness about novel drugs is anticipated to propel regional growth over the forecast period.
Asia Pacific is expected to witness lucrative CAGR during the forecast period owing to rising geriatric population base and improving economic conditions in emerging countries such as China and India. Moreover, an increase in healthcare expenditure by governments along with growing demand for cost-effective therapeutics will drive this region’s growth further.
Moreover, an increase in healthcare expenditure by governments along with growing demand for cost-effective therapeutics will drive this region's growth further.
Growth Factors:
- Increasing incidence of Bartter Syndrome
- Growing awareness about Bartter Syndrome and its treatment options
- Rising demand for novel therapeutics for the treatment of Bartter Syndrome
- Availability of government funding for research on Bartter Syndrome drugs
- Technological advancements in the field of drug discovery and development
Scope Of The Report
Report Attributes
Report Details
Report Title
Bartter Syndrome Drugs Market Research Report
By Type
NSAIDs (Nonsteroidal Anti-inflammatory Drugs), RAAS Inhibitors, Aldosterone Antagonists, Angiotensin II Receptor Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Abbott Laboratories, Novartis, Pfizer, Eli Lilly, Bristol-Myers Squibb, Abbott Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
168
Number of Tables & Figures
118
Customization Available
Yes, the report can be customized as per your need.
Global Bartter Syndrome Drugs Market Report Segments:
The global Bartter Syndrome Drugs market is segmented on the basis of:
Types
NSAIDs (Nonsteroidal Anti-inflammatory Drugs), RAAS Inhibitors, Aldosterone Antagonists, Angiotensin II Receptor Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Novartis
- Pfizer
- Eli Lilly
- Bristol-Myers Squibb
- Abbott Laboratories
Highlights of The Bartter Syndrome Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
- RAAS Inhibitors
- Aldosterone Antagonists
- Angiotensin II Receptor Blockers
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bartter Syndrome Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bartter syndrome drugs are medications that are used to treat the symptoms of Bartter syndrome. These medications can help improve blood flow, relieve pain, and reduce inflammation.
Some of the key players operating in the bartter syndrome drugs market are Abbott Laboratories, Novartis, Pfizer, Eli Lilly, Bristol-Myers Squibb, Abbott Laboratories.
The bartter syndrome drugs market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bartter Syndrome Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bartter Syndrome Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bartter Syndrome Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bartter Syndrome Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bartter Syndrome Drugs Market Size & Forecast, 2020-2028
4.5.1 Bartter Syndrome Drugs Market Size and Y-o-Y Growth
4.5.2 Bartter Syndrome Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
5.2.2 RAAS Inhibitors
5.2.3 Aldosterone Antagonists
5.2.4 Angiotensin II Receptor Blockers
5.2.5 Angiotensin-Converting Enzyme (ACE) Inhibitors
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bartter Syndrome Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bartter Syndrome Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
9.6.2 RAAS Inhibitors
9.6.3 Aldosterone Antagonists
9.6.4 Angiotensin II Receptor Blockers
9.6.5 Angiotensin-Converting Enzyme (ACE) Inhibitors
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
10.6.2 RAAS Inhibitors
10.6.3 Aldosterone Antagonists
10.6.4 Angiotensin II Receptor Blockers
10.6.5 Angiotensin-Converting Enzyme (ACE) Inhibitors
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
11.6.2 RAAS Inhibitors
11.6.3 Aldosterone Antagonists
11.6.4 Angiotensin II Receptor Blockers
11.6.5 Angiotensin-Converting Enzyme (ACE) Inhibitors
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
12.6.2 RAAS Inhibitors
12.6.3 Aldosterone Antagonists
12.6.4 Angiotensin II Receptor Blockers
12.6.5 Angiotensin-Converting Enzyme (ACE) Inhibitors
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
13.6.2 RAAS Inhibitors
13.6.3 Aldosterone Antagonists
13.6.4 Angiotensin II Receptor Blockers
13.6.5 Angiotensin-Converting Enzyme (ACE) Inhibitors
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bartter Syndrome Drugs Market: Competitive Dashboard
14.2 Global Bartter Syndrome Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories
14.3.2 Novartis
14.3.3 Pfizer
14.3.4 Eli Lilly
14.3.5 Bristol-Myers Squibb
14.3.6 Abbott Laboratories
